Polymeric alginate nanoparticles containing the local anesthetic bupivacaine

Journal of Drug Targeting

Volumn 18, Issue 9, 2010, Pages 688-699

  Grillo, Renato ^a   De Melo, Nathalie F S ^a,b   De Arajo, Daniele Ribeiro ^c   De Paula, Eneida ^b   Rosa, André Henrique ^a   Fraceto, Leonardo Fernandes ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSIDADE FEDERAL DO ABC   (Brazil)

Author keywords

Alginate; Bupivacaine; in vitro; in vivo; Polymeric nanoparticles

Indexed keywords

ALGINIC ACID; BUPIVACAINE; CHITOSAN; DOCUSATE SODIUM; NANOPARTICLE; NOVABUPI; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CLINICAL EVALUATION; CYTOTOXICITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; FIBROBLAST; IN VITRO STUDY; IN VIVO STUDY; LOCAL ANESTHESIA; MALE; MOUSE; NERVE BLOCK; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE; ZETA POTENTIAL;

ALGINATES; ANESTHETICS, LOCAL; ANIMALS; BUPIVACAINE; CHITOSAN; DRUG STABILITY; GLUCURONIC ACID; HEXURONIC ACIDS; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; SUCCINATES;

EID: 77957810932     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003649738     Document Type: Article

References (68)

1. Albright GA. (1979). Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology, 51, 285-287.
2. Alonso MJ. (2004). Nanomedicines for overcoming biological barriers. Biomed Pharmacother, 58, 168-172.
3. de Araújo DR, Braga AFA, Moraes CM, Fraceto LF, de Paula E. (2006). Mistura com excesso enantiomérico de 50% (S75-R25) de bupi-vacaina complexada com ciclodextrinas e anestesia por via sub-aracnoidea em ratos. Rev Bras Anestesiol, 56, 495-506.
4. de Araujo DR, Cereda CM, Brunetto GB, Pinto LM, Santana MH, de Paula E. (2004). Encapsulation of mepivacaine prolongs the analgesia provided by sciatic nerve blockade in mice. Can J Anaesth, 51, 566-572.
5. de Araujo DR, Cereda CM, Brunetto GB, Vomero VU, Pierucci A, Neto HS, de Oliveira AL, Fraceto LF, Braga Ade F, de Paula E. (2008a). Pharmacological and local toxicity studies of a liposomal formulation for the novel local anaesthetic ropivacaine. J Pharm Pharmacol, 60, 1449-1457.
6. de Araújo DR, Fraceto LF, Braga AFA, de Paula E. (2005). Sistemas de liberação controlada com bupivacaína racêmica (S50-R50) e mistura enantiomérica de bupivacaína (S75-R25): efeitos da complexação com ciclodextrinas no bloqueio do nervo ciático em camundongos. Rev Bras Anestesiol, 55, 316-328.
7. de Araújo DR, Pinto LMA, Braga AFA, de Paula E. (2003). Formulações de anestésicos locais de liberação controlada: aplicações ter-apêuticas. Rev Bras Anestesiol, 53, 663-671.
8. de Araujo DR, Tsuneda SS, Cereda CM, Del G F Carvalho F, Preté PS, Fernandes SA, Yokaichiya F, Franco MK, Mazzaro I, Fraceto LF, de F A Braga A, de Paula E. (2008a). Development and pharma-cological evaluation of ropivacaine-2-hydroxypropyl-beta-cyclo-dextrin inclusion complex. Eur J Pharm Sci, 33, 60-71.
9. Brasseur N, Brault D, Couvreur P. (1991). Adsorption of hematopor-phyrin onto poly-alkylcyanoacrylate nanoparticles: carrier capacity and drug release. Int J Pharm, 70, 129-135.
10. Calvo P, Vila-Jato JL, Alonso MJ. (1996). Comparative in vitro evalu-ation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci, 85, 530-536.
11. Cangiani LH, Cangiani LM, Pereira AM de SA. (2007). Bupivacaína com excesso Enantiomérico (S75-R25) a 0, 5%, bupivacaína racêmica a 0, 5% e lidocaína a 2% no bloqueio do nervo facial pela técnica de O'Brien: estudo comparativo. Rev Bras Anestesiol, 57, 136-146.
12. Casati A, Santorsola R, Aldegheri G, Ravasi F, Fanelli G, Berti M, Fraschini G, Torri G. (2003). Intraoperative epidural anesthe-sia and postoperative analgesia with levobupivacaine for major orthopedic surgery: a double-blind, randomized comparison of racemic bupivacaine and ropivacaine. J Clin Anesth, 15, 126-131.
13. Chavanpatil MD, Khdair A, Patil Y, Handa H, Mao G, Panyam J. (2007). Polymer-surfactant nanoparticles for sustained release of watersoluble drugs. J Pharm Sci, 96, 3379-3389.
14. Clarkson CW, Hondeghem LM. (1985). Mechanism for bupivacaine depression of cardiac conduction: fast block of sodium channels during the action potential with slow recovery from block during diastole. Anesthesiology, 62, 396-405.
15. Colombo P, Bettini R, Massimo G, Catellani PL, Santi P, Peppas NA. (1995). Drug difusion front movement is important in drug release control from swellable matrix tablets. J Pharm Sci, 84, 991-997.
16. Colombo G, Padera R, Langer R, Kohane DS. (2005). Prolonged duration anesthesia with lipid-protein-sugar particles containing bupivacaine and dexamethasone. J Biomed Mater Res, 75A, 458-464.
17. Coppi G, Iannuccelli V, Leo E, Bernabei MT, Cameroni R. (2002). Protein immobilization in crosslinked alginate microparticles. J Microencapsul, 19, 37-44.
18. Costa C, Lobo JMS. (2001). Modeling and comparison of dissolution profles. Eur J Pharm Sci, 13, 123-133.
19. Das RK, Kasoju N, Bora U. (2009). Encapulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine: Nanotechnol, Biol Med, 6, e153-e160.
20. Denizot F, Lang R. (1986). Rapid colorimetric assay for cell growth and survival. Modifcations to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods, 89, 271-277.
21. Douglas KL, Piccirillo CA, Tabrizian M. (2006). Efects of alginate inclusion on the vector properties of chitosan-based nanoparticles. J Control Release, 115, 354-361.
22. Durán N, Mattoso LHC, Morais PC (2006). Nanotecnologia. São Paulo, Brazil: Artliber.
23. Ferrero C, Muñoz-Ruiz A, Jiménez-Castellanos MR. (2000). Fronts movement as a useful tool for hydrophilic matrix release mechanism elucidation. Int J Pharm, 202, 21-28.
24. Gamisans F, Lacoulonche F, Chauvet A, Espina M, García ML, Egea MA. (1999). Flurbiprofen-loaded nanospheres: analysis of the matrix structure by thermal methods. Int J Pharm, 179, 37-48.
25. Gantenbein M, Abat C, Attolini L, Pisano P, Emperaire N, Bruguerolle B. (1997). Ketamine efects on bupivacaine local anaesthetic activity and pharmacokinetics of bupivacaine in mice. Life Sci, 61, 2027-2033.
26. González-Rodríguez ML, Holgado MA, Sánchez-Lafuente C, Rabasco AM, Fini A. (2002). Alginate/chitosan particulate systems for sodium diclofenac release. Int J Pharm, 232, 225-234.
27. Görner T, Gref R, Michenot D, Sommer F, Tran MN, Dellacherie E. (1999). Lidocaine-loaded biodegradable nanospheres. I. Optimization Of the drug incorporation into the polymer matrix. J Control Release, 57, 259-268.
28. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release, 57, 171-185.
29. Grant GJ, Bansinath M. (2001). Liposomal delivery systems for local anesthetics. Reg Anesth Pain Med, 26, 61-63.
30. Grillo R, de Melo NFS, de Araújo DR, de Paula E, Dias Filho NL, Rosa AH, Fraceto LF. (2009). Validation of an HPLC method for quantitative determination of benzocaine in PHBV-microparticles and PLA-nanoparticles. Latin Am J Pharmacy, 28, 393-399.
31. Guterres SS, Fessi H, Barratt G, Devissaguet J-Ph, Puisieux F. (1995). Poly (dl-lactide) nanocapsules containing diclofenac: I. Formulation and stability study. Int J Pharm, 113, 57-63.
32. Hariharan D, Peppas NA, Bettini R, Colombo P. (1994). Mathematical analysis of drug delivery from swellable systems with partial physical restrictions or impermeable coatings. Int J Pharm, 112, 47-54.
33. Haug A, Larsen B. (1962). Quantitative determination of the uronic acid composition of alginates. Acta Chem Scand, 16, 1908-1918.
34. Joo HH, Lee HY, Guan YS, Kim J-C. (2008). Colloidal stability and in vitro permeation study of poly(e-caprolactone) nanocapsules containing hinokitiol. J Ind Eng Chem, 14, 608-613.
35. Khan KA. (1975). Te concept of dissolution efciency. J Pharm Pharmacol, 27, 48-49.
36. Khan KA, Rhodes CT. (1972). A comparative evaluation of some alginates as tablet disintegrants. Pharm Acta Helv, 47, 41-50.
37. Kilic AC, Capan Y, Vural I, Gursoy RN, Dalkara T, Cuine A, Hincal AA. (2005). Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specifc antisense oligonucleotides to the NMDA receptors in the brain. J Microencapsul, 22, 633-641.
38. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm, 15, 25-35.
39. Korsmeyer RW, Peppas NA. (1991). Macromolecular and modeling aspects of swelling-controlled systems. In Roseman TJ, Mansdorf SZ, eds. Controlled Release Delivery Systems. New York, USA: Marcel Dekker, Inc.
40. Kuzma PJ, Kline MD, Calkins MD, Staats PS. (1997). Progress in the development of ultra-long-acting local anesthetics. Reg Anesth, 22, 543-551.
41. Lee DW, Yun KS, Ban HS, Choe W, Lee SK, Lee KY. (2009). Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J Control Release, 139, 146-152.
42. Leszczynska K, Kau ST. (1992). A sciatic blockade method to diferentiate drug-induced local anesthesia from neuromuscular blockade in mice. J Pharmacol Meth, 27, 85-93.
43. Li Z, Chen P, Xu X, Ye X, Wang J. (2009). Preparation of chitosansodium alginate microcapsules containing ZnS nanoparticles and its efect on the drug release. Mater Sci Eng C, 29, 2250-2253.
44. Magenheim B, Benita STP. (1991). Nanoparticle characterization: a comprehensive physicochemical approach. Pharma Sci, 1, 221-241.
45. Malamed SF. (2001). Manual de anestesia local. Rio de Janeiro, Brazil: Guanabara Koogan.
46. Martinsen AA, Skajak-Break G, Smidsrod O. (1997). Comparison of diferent methods for determination of molecular weight and molecular weight distribution of alginates. Carbohydr Polym, 15, 171-193.
47. Mi FL, Sung HW, Shyu SS. (2002). Drug release from chitosan-alginate complex beads reinforced by a naturally occurring crosslinking agent. Carbohydr Polym, 48, 61-72.
48. Mohanraj VJ, Chen Y. (2006). Nanoparticles-a review. Tropical J Pharm Res, 5, 561-573.
49. Moraes CM, Abrami P, de Paula E, Braga AF, Fraceto LF. (2007). HPLC and solubility study of the interaction between S (-) bupivacaine and hydroxypropyl-β-cyclodextrin. Int J Pharm, 331, 99-106.
50. Moraes CM, de Paula E, Rosa AH, Fraceto LF. (2008). Validaçã o de metodologia analítica por cromatografa líquida de alta efciência para quantifcação de bupivacaína (S75-R25) em nanoesferas de poli(lactídeo-co-glicolídeo). Quím Nova, 31, 2152-2155.
51. Moraes CM, Abrami P, de Araujo DR, Braga AFA, Issa MG, Ferraz HG, de Paula E, Fraceto LF. (2007). Characterization of lidocaine:hydroxypropyl-b- cyclodextrin inclusion complex. J Incl Phenom Macrocycl Chem. 57, 313-316.
52. Némati F, Dubernet C, Fessi H, Colin De Verdiere A, Poupon MF, Puisieux F, Couvreur P. (1996). Reversion of multidrug resistance using nanoparticles in vitro: infuence of the nature of the polymer. Int J Pharm, 138, 237-246.
53. Paavola A, Yliruusi J, Kajimoto Y, Kalso E, Wahlström T, Rosenberg P. (1995). Controlled release of lidocaine from injectable gels and efcacy in rat sciatic nerve block. Pharm Res, 12, 1997-2002.
54. Park CJ, Park SA, Yoon TG, Lee SJ, Yum KW, Kim HJ. (2005). Bupivacaine induces apoptosis via ROS in the Schwann cell line. J Dent Res, 84, 852-857.
55. de Paula E, Cereda CM, Tofoli GR, Franz-Montan M, Fraceto LF, de Araú, jo DR. (2010). Drug delivery systems for local anesthetics. Recent Pat Drug Deliv Formul, 4, 23-34.
56. Polakovic M, Görner T, Gref R, Dellacherie E. (1999). Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. J Control Release, 60, 169-177.
57. Rose JS, Neal JM, Kopacz DJ. (2005). Extended-duration analgesia: update on microspheres and liposomes. Reg Anesth Pain Med, 30, 275-285.
58. Sarmento B, Ferreira D, Veiga F, Ribeiro A. (2006). Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym, 66, 1-7.
59. Sarmento B, Ribeiro A, Veiga F, Neufeld R, Ferreira D. (2005). Insulinloaded alginate/chitosan nanoparticles produced by ionotropic pre-gelation. Rev Portugu Farmácia, LII, 139-140.
60. Schafazick SR, Guterres SS, Freitas LL, Pohlmann AR. (2003). Caracterização e estabilidade físico-química de sistemas poliméricos nanoparticulados para administração de fármacos. Quim. Nova, 26, 726-737.
61. Soppimath KS, Kulkarni AR, Aminabhavi TM. (2001). Chemically modifed polyacrylamide-g-guar gum-based crosslinked anionic microgels as pH-sensitive drug delivery systems: preparation and characterization. J Control Release, 75, 331-345.
62. Sriamornsak P, Tirawong N, Korkerd K. (2007). Swelling, erosion and release behavior of alginate-based matrix tablets. Eur J Pharm Biopharm, 66, 435-450. (Pubitemid 46756227)
63. Takka S, Acartürk F. (1999). Calcium alginate microparticles for oral administration: I: Efect of sodium alginate type on drug release and drug entrapment efciency. J Microencapsul, 16, 275-290. (Pubitemid 29191812)
64. Udelsmann A, Lorena SE, Girioli SU, Silva WA, de Moraes AC (2007). Hemodynamic efects of the acute intoxication with bupivacaine, levobupivacaine and 50% enantiomeric excess mixture: an experimental study in pigs. Rev Bras Anestesiol, 57, 63-73.
65. Venkatraman SS, Jie P, Min F, Freddy BY, Leong-Huat G. (2005). Micelle-like nanoparticles of PLA-PEG-PLA triblock copolymer as chemotherapeutic carrier. Int J Pharm, 298, 219-232. (Pubitemid 40828343)
66. Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ. (2002). Design of biodegradable particles for protein delivery. J Control Release, 78, 15-24.
67. You J, Peng C. (2005). Calcium-alginate nanoparticles formed by reverse microemulsion as gene carriers. Macromol Symp, 219, 147-153.
68. Zhang H, Lu Y, Zhang G, Gao S, Sun D, Zhong Y. (2008). Bupivacaineloaded biodegradable poly(lactic-co-glycolic) acid microspheres I. Optimization of the drug incorporation into the polymer matrix and modelling of drug release. Int J Pharm, 351, 244-249.